Moderna is trading 5.45% lower at $189.20 in pre-market on October 26 amid concerns over Phase 3 melanoma vaccine results. - With Merck’s Keytruda, intismeran reduced recurrence or death risk by 42%, versus 49% in an earlier study. - Detailed results were presented at ESMO; no new company announcement directly explaining the move was found. - Broader market indicators were mixed; pre-market volume was unavailable in the sources reviewed.